Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¹«Ç÷¼º °ñ±«»ç°¡ ¹ßº´ÇÑ ¾Ç¼º ¸²ÇÁÁ¾ 6¿¹ Avascular Necrosis of Bone Complicating Treatment of Malignant Lymphoma -Report of 6 cases -

´ëÇѾÏÇÐȸÁö 1997³â 29±Ç 2È£ p.344 ~ 351
¼Ò¼Ó »ó¼¼Á¤º¸
¼­ÇüÂù/Hyung Chan Suh ÇÑÁö¼÷/±è¹ü¼®/À̼®/Á¤¼Ò¿µ/¹ÎÀ¯Èï/°íÀ±¿õ/Jee Sook Hahn/Bum Seok Kimi/Seok Lee/So Young Chong/Yoo Hong Min/Yun Woong Ko

Abstract

¼­·Ð
¾Ç¼º ¸²ÇÁÁ¾Àº ÃÖ±Ù Áø´Ü¹æ¹ýÀÌ º¸´Ù ü°èÈ­µÇ°í Á¤È®ÇØÁü¿¡ µû¶ó ±× ºóµµ°¡ Áõ°¡µÇ°í ÀÖ
´Â Ãß¼¼À̸ç, Ä¡·á¸é¿¡¼­µµ º¹ÇÕÈ­Çпä¹ý ¹× ¹æ»ç¼±Ä¡·á µîÀÌ ¹ßÀüÇϸ鼭 Àå±â»ýÁ¸À» °¡´É
ÄÉ ÇÏ´Â ´ëÇ¥ÀûÀÎ Á¾¾çÀÇ Çϳª°¡ µÊ¿¡ µû¶ó Ä¡·áÈÄ ¹ß»ýÇÒ ¼ö ÀÖ´Â ÇÕº´Áõ¿¡ ´ëÇÑ °ü½ÉÀÌ
Á¡Â÷ Áõ´ëµÇ°í ÀÖ´Ù. ¾Ç¼º ¸²ÇÁÁ¾ ÀÚü ȤÀº Ä¡·á¿Í ¿¬°üµÈ ÇÕº´ÁõÀ¸·Î´Â ÀÌÂ÷¼º¾Ï, °¨¿°Áõ,
½ÅºÎÀü, °íÄ®½·Ç÷Áõ, Á¾¾ç¼¼Æ÷ÀÀÇØÁõ, °ñ¼ö±«»ç, Àü½ÅÇ¥ÇDZ«»ç, ºÒÀÓÁõ, ½ºÀ§Æ® ÁõÈıº,
Castleman¾¾ º´ ¹× ¹«Ç÷¼º °ñ±«»ç µîÀÌ ÀÖ´Ù.
¹«Ç÷¼º °ñ±«»ç´Â ÃøºÎ¼øȯÀÌ ºÒ·®ÇÑ °ñÁ¶Á÷À¸·ÎÀÇ Ç÷¾×¼øȯÀÌ Â÷´ÜµÇ´Â °æ¿ì ¹ß»ýÇϸç,
ºÎÀ§º°·Î´Â ´ëÅð°ñµÎ°¡ °¡Àå ÈçÈ÷ ħ¹üµÇ°í, ±×¿Ü »ó¿Ï°ñµÎ, ´ëÅð°ñ°ú»óµ¹±â µî¿¡¼­µµ ¹ß»ý
ÇÑ´Ù. ÀÌ ÁúȯÀÇ ¿øÀÎÀ¸·Î´Â °üÀýÀÇ ¿Ü»ó¼º Å»±¸¿Í °ñÀý, Gaucher¾¾ º´, °â»óÀûÇ÷±¸ ºóÇ÷,
¾ËÄÝÁßµ¶, Åëdz, ¹æ»ç¼± Á¶»ç ¹× ½ºÅ×·ÎÀ̵åÀÇ Àå±â »ç¿ë µîÀ» µé ¼ö ÀÖÀ¸¸ç, ¾Ç¼º ¸²ÇÁÁ¾
ȯÀÚ¿¡¼­´Â ½ºÅ×·ÎÀ̵峪 ¼¼Æ÷µ¶¼º Ç×¾ÏÁ¦, ¹æ»ç¼± Ä¡·á°¡ °ñ±«»çÀÇ º´Àο¡ °ü¿©ÇÒ °ÍÀ¸·Î
ÃßÁ¤µÇ³ª ÇöÀç±îÁö ¸íÈ®ÇÑ À¯¹ß±âÀüÀº Á¤¸³µÈ ¹Ù ¾ø´Ù. ¾Ç¼º ¸²ÇÁÁ¾¿¡¼­ ¹ß»ýÇÏ´Â ¹«Ç÷¼º
°ñ±«»ç´Â °ñÀÇ ¸²ÇÁÁ¾ ħÀ±À¸·Î ¿ÀÁøµÉ ¼ö ÀÖ´Â ¹Ù, Á¤È®ÇÑ Á¶±âÁø´ÜÀ» ÅëÇÑ Àû±ØÀûÀÎ Ä¡·á
¸¦ ½ÃÇàÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù ÇÒ ¼ö ÀÖ´Ù.
¾Ç¼º ¸²ÇÁÁ¾¿¡¼­ º¹ÇÕÈ­Çпä¹ýÀ̳ª °í¿ë·®ÀÇ ½ºÅ×·ÎÀ̵å Åõ¿©ÈÄ ¹ß»ýÇÑ ¹«Ç÷¼º °ñ±«»ç¿¡
´ëÇÑ ¿Ü±¹ÀÇ º¸°í´Â ÀÖ¾î ¿ÔÀ¸³ª ÇöÀç±îÁö ±¹³»¿¡¼­ÀÇ º¸°í´Â ¾ø´Â ¹Ù, ÀúÀÚ µîÀº ¼¼ºê¶õ½º
º´¿ø¿¡¼­ ¾Ç¼º ¸²ÇÁÁ¾À¸·Î Áø´Ü¹Þ°í Ä¡·áÈÄ º´¹ßµÈ ¹«Ç÷¼º °ñ±«»ç 6¿¹ÀÇ ÀÓ»ó¾ç»ó°ú Ä¡·á
¹× °æ°ú¿¡ ´ëÇØ °ËÅäÇÏ¿´´Ù.
#ÃÊ·Ï#
Background : Several reports have documented the association of avascular necrosis
(AVN) of bone and the treatment of malignant Iymphoma with steroid-containing
chemotherapy. It is important to recognize these conditions, as they can be mistaken (or
those of Iymphomatous involvement.
Cases : This report describes the experience at the Severance hospital over a 10-year
period with 6 patients in whom AVN developed during or following treatment of
malignant Iymphoma. Four patients of non-Hodgkin's Iymphoma and two of Hodgkin's
disease were treated with steroid-containing chemotherapy. The predominant symptom is
pain on motion or weight bearing. Symptoms leading to diagnosis of AVN developed
between 5 and 27 months after starting prednisolone (mean 17.8 months), and the mean
cumulative dose of prednisolone to the onset of AVN was 4,447 mg(range, 1,800¡­9,490
mg). All but one were involved in both hip joint. Diagnosis was based on the radiologic
appearance, and in the majority radiographic changes consistent with AVN were present
at the time of presentation of symptoms. Four patients received total hip replacement
and two had conservative care.
Conclusion : Patients with malignant lymphoma who developed pain on joint during or
after the use of steroid-containing chemothearpy should be carefully investigated with
MRI and radionuclear bone scan for early diagnosis and proper management.

Å°¿öµå

Avascular necrosis; Malignant lymphoma; Steroid;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS